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Background: Malaria anaemia is still a major public health problem and its pathogenesis still unclear. Interestingly,
the progression of anaemia is at relatively low parasitaemia with some mortality in the semi-immune individuals in
the endemic areas despite adequate erythropoietin (EPO) synthesis. A recent study has shown that treatment with
exogenous anti-erythropoietin (anti-EPO) antibodies (Ab) of infected mice gives protection against malaria infection,
suggesting an important role for anti-EPO Ab in malaria. The objective of the study was to evaluate anti-EPO
antibody levels in anaemic condition of different strains of semi-immune mice with malaria.
Methodology: Semi-immune status was attained in four mice strains (Balb/c, B6, CBA and NZW) by repeated
infections with 104 Plasmodium berghei ANKA, and treatment with chloroquine/pyrimethamine. ELISA was used to
measure anti-EPO Ab, transferrin and EPO while inflammatory cytokines measurement was done using bead-based
multiplex assay kit.
Results: The mean anti-EPO Ab levels in the mice strains [Optical Density (OD) values at 450 nm: Balb/c (2.1); B6
(1.3); CBA (1.4) and NZW (1.7)] differed (p = 0.045), and were significantly higher when compared with uninfected
controls, p < 0.0001, and mean anti-EPO Ab levels in the mice strains at recovery [OD values at 450 nm: Balb/c (1.8);
B6 (1.1); CBA (1.5) and NZW (1.0) also differed (p = 0.0004). Interestingly, EPO levels were significantly high in NZW
and low in Balb/c mice (p < 0.05), with those of B6 and CBA of intermediary values. Again, NZW were highly
parasitaemic (20.7%) and the other strains (Balb/c, B6 and CBA) ranged between 2.2-2.8% (p = 0.015). Anti-EPO Ab
correlated positively with extent of Hb loss (r = 0.5861; p = 0.003). Correlation of anti-EPO antibody with EPO was
significant only in Balb/c mice (r = −0.83; p = 0.01). Significant levels of IL6 and IFNγ (p < 0.0001), both known to be
associated with erythropoiesis suppression were observed in the Balb/c. Transferrin was significantly lower in Balb/c
(p < 0.0001) when compared with the other mice strains (B6, CBA and NZW).
Conclusion: This is the first ever report in estimating endogenous anti-EPO antibodies in malaria anaemia. The data
presented here suggest that anti-EPO Ab is produced at infection and is associated with Hb loss. Host factors
appear to influence anti-EPO antibody levels in the different strains of mice.
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Malarial infections result in a significant destruction of
both infected red blood cells (iRBC) and uninfected red
blood cells. It has been observed in chronic infected
individuals or in the semi-immune, that the anaemia
reported does not correlate with the level of parasit-
aemia [1,2]. Possible mechanisms that have been sug-
gested are defective production of RBC or an excessive
rate of red cells destruction or a combination of both
[3,4]. However, studies have shown that erythropoietin
(EPO) level is adequate in infected children and experi-
mental models [5-7], and thus it is surprising that an-
aemia is not improved in that measure. Erythropoietin
(EPO), a glycoprotein hormone, being a cytokine con-
trols erythropoiesis or red blood cell production.
Studies in some auto-immune diseases and HIV patients
revealed high level of anti-EPO auto-antibodies and its as-
sociation with anaemia [8-10]. But this has not been stud-
ied in malaria anaemia cases. The use of EPO in therapy
has been recommended to alleviate anaemia due to malar-
ial infections [11] and also in cerebral malaria manage-
ment [12]. The suggestion is that use of EPO will help a
great deal in minimizing the risk of HIV/AIDS via blood
transfusion when not screened properly. Meanwhile, EPO
has been used successfully in a couple of diseases, treating
anaemia in AIDS [13], in renal failure [14], as well as for
limiting brain damage in experimental auto-immune en-
cephalomyelitis [15], and also been proposed for treatment
of haemoglobinopathies in which β-globin synthesis is af-
fected [16,17]. These suggest an important role for EPO in
therapy. However, neutralizing IgG antibodies to the pro-
tein component of exogenous recombinant EPO are found
to cross-react with endogenous erythropoietin. Thus, the
question that remains to be clarified is whether antibodies
are produced against endogenous EPO and what the im-
plications are during Plasmodium infections.
High level of anti-EPO auto-antibodies has been ob-
served in some auto-immune diseases, but not reported
in malaria anaemia (which has been thought to be auto-
immune mediated). As a result anti-EPO antibodies may
be implicated in malaria anaemia cases. Therefore, a
study evaluating the levels of anti-EPO antibodies in
malaria anaemia will be of interest to assess the benefits
and/or predict (un)expected complications that may
arise in the administration of exogenous EPO as thera-
peutic measure in malaria anaemia cases. Related to that,
induction of antibodies against EPO molecule was ob-
served in patients treated with recombinant human EPO
which resulted in pure red cell aplasia [18]. Furthermore,
the use of anti-EPO auto-antibodies as a therapy in mur-
ine malaria studies [19], is an indication of the important
role it may play in severe malaria anaemia.
A previous study has shown that one mechanism of an-
aemia during Plasmodium infection was the destruction ofuninfected red blood cells [2]. The current study aims to
describe an alternative mechanism of anaemia by using
sera raised from this previous study. Thus, the level of
anti-EPO antibodies in malaria anaemia situation of differ-
ent strains of semi-immune mice was evaluated. Further-
more, to investigate if host factors may play a role,
different strains of semi-immune mice were used.
Methods
Mice, infection and generation of semi-immune status
The procedure for this method has been reported else-
where [2]. Briefly, four strains of mice BALB/c, C57BL/6
(B6), CBA and New Zealand White (NZW) aged 8 weeks
supplied by SLC laboratories, Fukuoka, Japan, were
injected intraperitoneally (i.p.) with 104 Plasmodium
berghei ANKA (PbANKA)–iRBCs. Parasitaemia and re-
ticulocyte levels were monitored every two days by
Giemsa-stained thin blood film and are expressed as a per-
centage of more than 500 RBCs. Haemoglobin (Hb) was
measured in a 96-well plate at 570 nm on Bio-Rad Model
3550 Micro plate Reader as previously described [2]. A re-
cent study [20] has shown that estimates of polychromato-
philic cells as done after Giemsa staining in this study are
typically less than percentages of reticulocytes. However,
Giemsa has been successfully used previously for reticulo-
cyte staining [1,2]. Four microlitres of tail-vein blood was
suspended in 1 mL Drabkin reagent (Sigma, St Louis, MO)
and absorbance measured, and is expressed as a percentage
of baseline levels. To generate semi-immune status, mice
were treated at day 6 after infection with chloroquine/
(10 mg/kg intraperitoneally) and pyrimethamine (10 mg/kg
intraperitoneally) daily for 6 days. During subsequent
rounds of infection, mice were rested for two weeks before
being rechallenged with 104 PbANKA, then monitored
and drug-cured prior to parasitemia reaching 5%. The mice
strains were taken through 7 cycles of infection and treat-
ment to generate the semi immune status, Figure 1. After
the 7th cycle of infection and treatment (Figure 1), parasit-
aemia was checked and when it was negative (zero), which
is the recovery stage, blood was collected from the tail, and
serum harvested for analysis before the final cycle of infec-
tion without treatment. During the final cycle of infection
(without treatment), mice were monitored every other day
and, on days in which minimum Hb drop (i.e. maximum
Hb reduction) was observed, blood was collected and sera
were harvested for analysis, as described previously [2].
Sera were stored at −30°C until used. The sera used in this
study were raised in previous study [2]. The parasitaemia
and haematological profile of all the mice strains were,
therefore, not reported here.
Ethical statement
The study was conducted strictly according to the rec-
ommendation in the Fundamental Guidelines for Proper
Figure 1 Parasitaemia and haemoglobin profile in the mice strains during the seven cycles of infection and treatment. The above data
are representative data of one mouse per strain. Red arrows refer to infection with 104 Plasmodium berghei ANKA; blue arrows refer to treatment
with chloroquine/pyrimethamine; green arrows refer to blood harvested at recovery after two weeks rest; black arrows refer to blood harvested
during infection. Recovery refers to time at which mice has been rested for two weeks after treatment with chloroquine/pyrimethamine for 6
days or until parasitaemia is zero. Upper left graph a refers to profile for Balb/c; upper right graph b refers to profile for B6; lower left graph c
refers to profile for CBA and lower right graph d refers to profile for NZW.
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Academic Research Institutions under the jurisdiction of
the Ministry of Education, Culture, Sports, Science and
Technology, Japan (Notice no. 71). All animal experiments
were approved by the Nagasaki University, Board of Ani-
mal Research, according to Japanese Guideline for use of
experimental animals (Permit Number 0811130716). All
efforts were made to humanely minimize animal suffering.
Screening of sera for anti-EPO antibodies by
immunodot blot
Ultrabind US450 membrane (Gelman Sciences, Japan)
was cut according to size and pre-wet with enough vol-
ume of tris-buffered saline (TBS). The membrane was
placed unto the manifold and 300 μL TBS used to wash
wells and membranes. Recombinant mouse EPO (R&D
Systems, Japan, Catalogue Number 959-ME) was used as
antigen to coat the membrane overnight at 4°C. The
membrane in each well was blocked with 100 μL
BlockAce (Catalogue No. UK-B25, Dainippon Pharma-
ceutical Co. Osaka, Japan) for an hour. Membranes in
the wells were later washed once with 300 μL tris-
buffered saline with tween (TTBS). Primary antibody(from infected sera and uninfected mice sera as negative
control) were diluted at 1:10, 1:20 and incubated with
the mouse EPO antigen for 3 hours at RT. The mem-
branes in the wells were washed with 300 μL of TTBS
twice before they were finally removed from the mani-
fold and washed once in TTBS on a rotating machine.
Secondary antibody of goat anti-mouse IgG-conjugated
horse-radish peroxidase (HRP) at 1:2,000 dilution was incu-
bated with the membrane for an hour at room temperature
(RT) in the dark. Membrane was washed four times with
TTBS and once with TBS to remove residual TTBS from
membrane. Color development was done by addition of
diaminobenzidine (DAB, at 5.0 mg/10 ml PBS + 5 uL H202)
and incubated at RT for 10–15 min.
Measurement of anti-EPO antibodies
This was done based on modified method according to
Tzioufas et al. [9]. The recombinant mouse EPO (R&D
Systems, Japan, Catologue Number 959-ME) was used
as antigen. It was dissolved in phosphate buffered saline
(PBS, pH 7.2), and coated in the polystyrene micro titer
plate at 0.09 μg per well. After incubation overnight at
4°C, plates were washed with 0.1% Tween 20/PBS and
Figure 2 Detection of Anti-EPO antibody in sera of different
semi-immune mice strains and control at different dilution. Sera
was taken from blood harvested at minimum Hb (i.e. maximum Hb
reduction) and screened for anti-EPO antibody by immunodot blot.
The above data are representative data for each semi-immune mice
strain. Number of mice used is two per strain. Direction of arrows
indicate extent of serum dilution by a factor of 2. Upper panel (a)
shows immuno dot blot for Balb/c; panel (b) immediately below
(that of Balb/c) is the immuno dot blot for B6 and CBA while the
third lowest panel (c) is the immuno dot blot for NZW and lower
panel (d) is the immuno dot blot for uninfected control mice.
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B25, Dainippon Pharmaceutical Co. Osaka, Japan) for
1 hour. Diluted serum samples from the infected mice
and uninfected mice (serving as negative control) all at
1:1,000 dilutions was added to the wells in duplicate and
incubated for three hours at 37°C. After washing for
five times with 0.1% Tween 20/PBS, 100 μL horse ra-
dish peroxidase (HRP)-conjugated goat anti-mouse IgG
(Catalogue number 55563, MP Biomedicals, LLC 29525
Fountain Pkwy Solon, OH 44139, USA) at 1:2,500 was
added to the wells in the 96-well ELISA plates and incu-
bated for an hour at RT. Washing was done five times
with 0.1% Tween 20/PBS and reaction visualized by the
addition of 100 μL stabilized chromogen (Part/Lot num-
ber SS01/302008, Biosource, Carmarillo, CA, USA). Re-
action was stopped 20 minutes later by the addition of
50 μL 1 N H2SO4 and absorbance was measured in the
ELISA reader machine at 450 nm.
Measurement of EPO levels
Measurement of mouse EPO was done according to
manufacturer’s instructions of the Quantikine ELISA kit
for mouse/rat EPO Immunoassay (R and D Systems,
Japan, Catalogue number MEP00). Briefly 50 μL of stan-
dards, control and samples were pipette into the wells of
a monoclonal antibody specific for mouse/rat EPO pre-
coated micro- plate, which already has 50 μL of the
assay diluents added. This was incubated at RT for 2 h
on a shaker. The wells were washed five times and
100 μL of the conjugate added, then incubated at RT for
2 h on the shaker. Again washing was done five times
with 100 μL substrate solution added to each well and
incubated for 30 min on the bench top in the dark. After
100 μL stop solution was added to each and OD read at
450 nm.
Measurement of inflammatory cytokines
Cytokines measurement was done using Procarta Mouse
Cytokine Assay Kit plex according to manufacturer’s in-
structions (Luminex, Affymetrix). Briefly, filter plate was
wetted with reading buffer and incubated at room
temperature for 5 min, then filtered. Antibody beads
(50 μL) were added to each well, filtered and washed
once with 150 μL of washing buffer. Twenty-five micro-
litres of serum standard buffer was added to all the sam-
ple wells, and later equal volume (25 μL) of serum was
added to each well, incubated at room temperature for
60 min. Later, washing was done three times, after which
25 μL premixed detection antibody was added, incu-
bated for 30 min on the shaker at room temperature.
After, washing and filtration was done three times. Dur-
ing each wash 150 μL of washing buffer was used.
Streptavidin-PE (50 μL) was later added and incubated
for 30 min, later washed and filtered three times. Afterthe third wash the plate was prepared for analysis. Read-
ing buffer (120 μL) was added to each instrument.
Measurement of transferrin
Serum transferrin was measured according to manufac-
turer’s instruction (ELISA kit from Alpha diagnostic Inter-
national, USA, Catologue number 6390). Briefly, 100 uL of
calibrators, control and samples were pipette into pre-
designated wells already coated with anti-transferin anti-
bodies, all in duplicates. This was incubated at room
temperature (RT) for thirty minutes. The plate was co-
vered during incubation. The contents of the wells were
aspirated following incubation. Thereafter, each well was
completely filled with diluting wash solution and aspi-
rated. This was repeated three times, for a total of
four washes. Thereafter, 100 uL of appropriately diluted
enzyme-antibody conjugate was added to each well and
incubated at room temperature for 30 min in the dark.
The plate was covered and kept level during incubation.
Washing was done and plates blotted four times as
done previously. Thereafter, 100 μL of 3,3′,5,5′ tetrame-
thylbenzidine (TMB) was added to each well and incu-
bated for 10 min in the dark; after which 100 uL of stop
solution was added to each well. The absorbance of each
well was read at 450 nm.
Figure 3 Levels of anti-EPO antibody in the semi-immune mice at infection and recovery. These are anti-EPO antibody level at infection
and recovered (R). Blood was harvested for serum at minimum Hb (i.e. maximum Hb reduction, at infection) and recovery (when parasitaemia is
cleared). Means of Anti-EPO Ab at infection and recovery differed, p = 0.045 and 0.0004 respectively. *Balb/c values significantly higher when
compared with B6 (p < 0.05). **Balb/c values at recovery different from B6 and NZW (p < 0.05). #Significantly lower when compared with the
others at infection and recovery (p < 0.0001). Values at infection and recovered differed (p = 0.0008). Recovery refers to time at which mice has
been rested for two weeks after treatment with chloroquine/pyrimethamine for 6 days or until parasitaemia is zero. Values are means and errors
bars being standard deviation (SD). Data was analysed by ANOVA after they were log10 transformed. n refers to number of samples. These are
pooled data of two separate experiments. Un Control means uninfected control (consist of 2 mice per strain, giving a total of 8 mice).
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Data analysis was done using the GraphPad Prism Ver-
sion 5.00 for Windows, GraphPad Software, San Diego
California, USA, [21]. Data are expressed as the mean
with standard deviation (SD) unless otherwise stated.
Data were log transformed to ensure normal distribution
before one-way analysis of variance (ANOVA, with
Tukey’s post-test, two tailed), were performed. Pearson
correlation analysis was performed on the transformed
data of variables to compare the relationship between
them. Values were considered significant when p < 0.05.Figure 4 Correlation between %Hb loss and anti-EPO antibody
(all mice combined). Total number of samples n = 23 (Balb/c (8), B6
(5), CBA (6), NZW (4)). Dotted lines are 95% confidence intervals and
the continuous line is the line of best fit. r is Pearson coefficient.
Blood was harvested at minimum Hb in the course of monitoring
the haematological and parasitological parameters. These are values
of two separate experiments.Results
High levels of anti-EPO antibody in the semi-immune
mice strains
Sera of the mice strains were screened by immunodot blot
for the possible identification of anti-EPO antibody levels.
It can be seen from Figure 2 that sera from all the mice
strains showed the presence of anti-EPO antibody, but
negative for uninfected control sera, suggesting that parasit-
aemia might contribute to the production of the anti-EPO
antibody. The anti-EPO antibody levels were measured, at
infection and at recovery. Anti-EPO antibody was signifi-
cantly different in the mice strains (mean OD450nm values:
Balb/c (2.1); B6 (1.3); CBA (1.4); NZW (1.7)) at infection
(p = 0.045). While Balb/c anti-EPO Ab levels at infection
differed from B6 (p < 0.05), the others were not significantlydifferent when paired. The anti-EPO antibody is signifi-
cantly higher in all four mice strains at infection when
compared with the uninfected control (mean OD450nm
value = 0.1) (p < 0.0001). Anti-EPO Ab levels at recovery in
the mice strains (Balb/c, 1.8; B6, 1.1; CBA, 1.5; NZW, 1.0)
were significantly different, p = 0.0004. Again anti-EPO Ab
Figure 5 Correlation between %Hb loss and anti-EPO antibody (per mice strains). Total number of samples n = 23 (Balb/c (8), B6 (5), CBA
(6), NZW (4)). Dotted lines are 95% confidence intervals and the continuous line is the line of best fit. r is Pearson coefficient. Blood was harvested
at minimum Hb in the course of monitoring the haematological and parasitological parameters. These are values of two separate experiments.
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that of B6 and NZW (p < 0.05), while the others did not dif-
fer (p > 0.05). The means of anti-EPO Ab levels at infection
and recovery differed (p = 0.0008) (Figure 3).
Association of anti-EPO antibody with Hb loss
To explore the association of anti-EPO antibody with
anaemia, the level of anti-EPO antibody was plotted
against Hb loss in all the mice strains giving interestingFigure 6 EPO levels in the semi-immune mice strains at infection and
and at recovery. *Values at recovery are significantly lower than at infection
significantly different for all the mice strains. Recovery refers to time at whi
chloroquine/pyrimethamine for 6 days or until parasitaemia is zero. OD val
it was transformed to log10. Values are means and errors bars being standa
transformed, with Tukey’s post test. n refers to number of samples. These aresults as seen in Figure 4 (combined results for all the
mice strains) and Figure 5 (individually). Anti-EPO anti-
body correlated significantly with Hb loss when all the
mice strains was combined, Figure 4 (r = 0.5681; p = 0.003).
Plotting anti-EPO antibody against Hb loss per mice
strains (Figure 5), it was observed that the correlation was
significant (r = 0.7651; p = 0.028) in only Balb/c but not in
other strains B6 (r = 0.304; p = 0.5991), CBA (r = 0.2592;
p = 0.619) and NZW (r = 0.8223; p = 0.1777).recovery. Blood was harvested for serum at minimum Hb at infection
for all the mice strains (p < 0.01). Values at recovery were not
ch mice has been rested for two weeks after treatment with
ues from ELISA were converted to EPO concentration of pg/ml before
rd deviation (SD). Data was analysed by ANOVA after they were log
re pooled data of two separate experiments.
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To further understand the erythropoietic response in all the
semi-immune mice strains the EPO levels were evaluated
at both infection and at recovery. It was consistently ob-
served for each mice strain that, EPO at recovery was sig-
nificantly lower than that at infection (Figure 6), confirming
earlier reports [5-7]. However, when EPO levels at infection
was compared in all the mice strains, EPO levels in NZW
was significantly higher than Balb/c (p < 0.05).
Since EPO level is a measure of how active the individ-
ual is able to respond to Hb drop, the association of
EPO level with the anti-EPO antibody level in all the
semi-immune mice strains was analyzed but found no
significant correlation. However, when this association
was analysed per mice strain, a significant negative asso-
ciation was found only in Balb/c mice strain at infection
stage, Figure 7 (r = −0.83; p = 0.01). No significant associ-
ation was found in the other mice strains both at infec-
tion and recovery, Figure 7.Figure 7 Correlation between EPO and anti-EPO antibody at infection
harvested for serum at minimum Hb at infection and at recovery for EPO a
methods. Number (n) of mice per strain at infection, Balb/c (n = 8), B6 (n =
B6 (n = 8), CBA (n = 5) and NZW (n = 5)). Graph a. upper left is correlation
is correlation for CBA; graph d. is correlation for NZW. Continues line is the
two experiments. Log10 transformation of EPO was done on the EPO conc
ELISA readings. Anti-EPO antibody values (OD values) were also log10 transCytokine levels and their relationship with anti-EPO
antibody in the semi-immune mice strains
While IL-6 and INF-γ are known to suppress erythropoi-
esis, TNF and IL-10 are thought to contribute to the de-
gree of anaemia in children with falciparum malaria
[22,23]. These cytokines were measured to evaluate the
extent to which they may be implicated in anaemia and
anti-EPO antibody production indirectly. IL-17 is thought
to be associated with autoimmunity. Significantly high
levels of IL6, IL-17 and INF-γ were observed in Balb/c,
p < 0.05 (Table 1). Interleukin 10 (IL-10) and TNF were
similar in all the mice strains, p = 0.08, 0.07 respectively;
TNF/IL10 ratio on the other hand were significantly
different in all the mice strains, p = 0.02. To further
understand the relationship between the cytokines and
anti-EPO antibody, anti-EPO antibody was plotted against
the cytokine levels. It was observed that there was no cor-
relation (p > 0.05) between all the cytokines and anti-EPO
antibody in all the mice strains.and recovery of all the semi-immune mice strains. Blood was
nd anti-EPO antibody measurement as indicated in materials and
7), CBA (n = 7) and NZW, (n = 6); and at recovery, Balb/c (n = 8),
for Balb/c; graph b. upper right is correlation for B6; graph c. lower left
line of best fit, while r is Pearson coefficient. These are pooled data of
entration of pg/ml after being converted from OD values from the
formed.




P value*Balb/c (8) B6 (4) CBA (6) NZW (4) Uninfected control (4)
IL6 (SD)
6692.0 513.1a 136.7b 464.1d 71.60c
0.0001
(4443.0) (757.9) (76.8) (664.6) (30.63)
IL17 (SD)
6052.0 205.3a 4.59b 89.7d 4.05c
< 0.0001
(4202.0) (323.0) (0.71) (121.0) (0.5)
IL10 (SD)
13.97 12.51 23.14 16.31 4.625
0.08
(12.67) (5.9) (33.3) (10.15) (1.33)
INFγ (SD)
6785.0 715.7 93.74b 413.9d 6.5c
0.001
(4805.0) (1218.0) (83.7) (799.8) (0.38)
TNF (SD)
54.86 202.5 16.24 18.65 16.15
0.07
(35.4) (410.4) (1.08) (3.835) (3.85)
TNF:IL10 (SD)
4.5 1.7 1.5 1.5 4.0
0.002
(1.0)# (0.6) (0.7) (0.9) (2.4)
Blood was harvested for serum at minimum Hb. Values are pooled data of two separate experiments. *P values done by ANOVA was performed on the log10
transformed data. Analysis was done by ANOVA with Tukey’s post test. a, b, c, d Statistically lower than Balb/c. #Significantly higher than the other strains.
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Transferrin is known to regulate iron metabolism and
also an indicator of inflammatory response during infec-
tion. Thus, to evaluate the extent to which iron is me-
tabolized at minimum Hb (maximum Hb reduction, see
Figure 1 in [2]) and possible implication with immune
response transferrin levels were measured at infection
and found out that the levels was significantly low in the
Balb/c when compared with the other mice strains. An
elevated level of transferrin was also observed at infec-
tion for all the semi-immune mice strains when com-
pared with the uninfected mice (Figure 8).
Discussion
To the knowledge of the authors this is the first report
evaluating the levels of endogenous anti-EPO antibodies
during malarial infection. The study describes a correl-
ation between anti-EPO antibody with Hb loss. The data
presented here show that anti-EPO antibody is producedFigure 8 Transferrin levels in the semi-immune mice strains. Blood wa
mice strains and significantly higher than uninfected control (p < 0.0001). B
than uninfected control. Values were log10 transformed and analysed withduring malaria infection. It is also observed in this study
that host genetic factors are playing a role in the extent of
anti-EPO antibody production during anaemic condition.
The positive correlation of anti-EPO antibody with %Hb
loss (in Balb/c) and EPO levels in this study has been
observed in another study of auto-immune condition [9].
This study, however, do not have enough data to suggest a
neutralizing effect anti-EPO antibody has on EPO during
Hb loss, to keep a certain minimum amount of RBC in
the pool until parasite is cleared. Further studies to
evaluate that will be very informative. It is interesting
to note that Balb/c which has relatively low parasit-
aemia, high survival rate [2], has a significant positive
correlation of anti-EPO antibody with %Hb loss and
EPO levels. The low EPO level observed in this study,
indicative of low iron level; and a relationship with pro-
tection has been observed in a recent field data in
humans [24]. The explanation is that during low iron
level an unfavourable internal environment is createds harvested for serum at minimum Hb. *Significantly lower than all the
6, CBA and NZW are not significantly different but significantly higher
ANOVA. These are pooled data from two separate experiments.
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This agrees with nutritional immunity from a study on
bacterial infections where protection for individuals with
iron deficiency on disease severity was observed [25].
In this study, no significant correlation between anti-
EPO antibody and the cytokine levels in all the mice
strains was observed. However, it is tempting to indicate
that the significantly high levels of IL-6, IL-17 and INF-γ
observed in Balb/c, (Table 1), may signify synergistic ef-
fect between them and anti-EPO antibody resulting in
low parasitaemia hence high survival, due to low iron
level. It is not clear why similar trend of inflammatory
cytokine was not observed in CBA and B6 even though
similar parasitaemia was observed in them and Balb/c.
Low-density parasitaemia and its treatment have been
found to induce a mild increase in IL-6 and serum
hepcidin concentrations [26]. Thus the high level of IL-6
may impair bioavailability of iron resulting in low iron
level leading to low parasitaemia. High levels of these
two cytokines (IL-6 and INF-γ) in Balb/c suggest sup-
pression of erythropoiesis but the mechanism(s), how-
ever, remain to be clarified. This findings support other
studies where IL-6 and INF-γ were postulated to sup-
press erythropoiesis [27]. Even though TNF and IL-10
are thought to contribute to the degree of anaemia in
children with falciparum malaria, no significant differ-
ence was observed among the mice strains in this study,
and even when compared with uninfected control. IL-17
promotes inflammation [28] by activating cells to pro-
duce more pro-inflammatory cytokines and also thought
to be associated with autoimmunity [29] suggesting that
these phenomena may be associated more with Balb/c.
The hall mark of malaria in acute cases is anaemia.
This type of anaemia occurs within a very a short period
and sudden. However, this study mirrors chronic infec-
tion as is the case of individuals in malaria endemic
areas where persistent low Hb is observed for a relatively
long period of time. Many chronic infections such as
malaria are characterized by a generalized state of chro-
nic inflammation. Furthermore, low Hb level is associ-
ated with chronic infection thus low iron level. Another
way of estimating iron level in the serum is via transfer-
rin level. Although transferrin is involved in iron traf-
ficking [30,31], it is also an indicator of inflammatory
response [32]. Thus, transferrin being an acute phase
reactant gets elevated in inflammatory response due to
malaria infection. This study concurs with this observation
where in all the mice strains; transferrin level was signifi-
cantly higher in the infected and recovered semi-immune
mice than the uninfected level (Figure 8). Considering the
extent to which these inflammatory cytokines (IL-6 and
INF-γ) could be interacting with anti-EPO antibody to
lower iron level, resulting in relatively low parasitaemia as
discussed above; it was surprising to observe significantlylow level of transferrin in Balb/c. This is because a patient
with an increased serum transferrin level often suffers
from iron deficiency anaemia [33]. On the other hand a
patient with decreased plasma transferrin can suffer from
iron overload diseases and protein malnutrition. This
shows that transferrin imbalance can have serious health
effects for those with low or high serum transferrin levels.
Balb/c having the least level of transferrin also suggests
that they (Balb/c) had the most inflammatory process,
which is backed by relatively high levels of IL-6 and INF-γ
in Balb/c than the other mice strains (Table 1). Addition-
ally, clinical significance of low transferrin level may be in-
dicative of liver damage as a result of liver iron overdose.
Also elevated levels of transferrin in the other mice strains
are indicative of enhanced erythropoiesis and relatively
lower inflammatory response as compared to Balb/c.
In conclusion, the data presented here show that
Plasmodium infection influences anti-EPO production
in all mice strains; and correlates more with Hb loss in
one mice strain suggesting host factors is involved. Fur-
ther studies to evaluate the kinetics of the anti-EPO anti-
body and its neutralization of EPO activity will help
deduce and understand further the development of an-
aemia in malaria.
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